12 Sato K, Nagayama H, Takahashi TA. Aberrant CD3- and CD28-mediated signaling events in cord blood T cells are associated with dysfunctional regulation of Fas ligand-mediated cytotoxicity. *J Immunol* 1999; **162**: 4464–4471.

13 Hill RS, Peterson FB, Storb R et al. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. *Blood* 1986; **67**: 811–816.

14 Huss R, Deeg HJ, Gooley T et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence, and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. *Bone Marrow Transplant* 1996; **18**: 767–776.

15 Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. *Blood* 1997; **89**: 3048–3054.

16 Yu C, Seidel K, Nash RA et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-non-identical unrelated marrow grafts. *Blood* 1998; **91**: 2581–2587.

17 Storb R, Yu C, Barnett T et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. *Blood* 1999; **94**: 1131–1136.

18 Storb R, Yu C, Zaucha JM et al. Stable mixed hematopoietic

19 Storb R, Yu C, McSweeney P. Mixed chimerism after transplantation of allogeneic hematopoietic cells. In: Thomas ED, Blume KG, Forman SJ (eds). *Hematopoietic Cell Transplantation*, 2nd edn. Oxford University Press: Malden, MA, 1998, pp 287–295.

20 Thomson BG, Robertson KA, Gowan D et al. Analysis of engraftment, graft-versus-host disease, and immune recovery following unrelated donor cord blood transplantation. *Blood* 2000; **96**: 2703–2711.

21 Ab-Ghosh A, Goldman S, Slone V et al. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. *Bone Marrow Transplant* 1999; **24**: 535–544.

22 Giraud P, Thuret I, Reviron D et al. Immunue reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience. *Bone Marrow Transplant* 2000; **25**: 53–57.

23 Laughlin MJ, Barker J, Bambach B et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. *New Engl J Med* 2001; **344**: 1815–1822.

24 Giunan EC, Boussiotis VA, Neuberg D et al. Transplantation of anergic histoincompatible bone marrow allografts. *New Engl J Med* 1999; **340**: 1704–1714.

chimerism in dogs given donor antigen, CTLA-4Ig, and 100cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. *Blood* 1999; **94**: 2523–2529.

Editor-Communicated Paper

Efficient Adeno-Associated Virus-Mediated Gene Expression in Human Placenta-Derived Mesenchymal Cells

Xiaohong Zhang[1,3], Takashi Nakaoka[*,1], Toshihide Nishishita[1], Nobukazu Watanabe[2], Koichi Igura[2], Ken-ichi Shinomiya[3], Tsuneo A. Takahashi[2], and Naohide Yamashita[1]

[1]Department of Advanced Medical Science, and [2]Division of Cell Processing, The Institute of Medical Science, The University of Tokyo, Minato-ku, Tokyo 108–8639, Japan, and [3]Section of Orthopaedic and Spinal Surgery, Department of Frontier Surgical Therapeutics, Division of Advanced Therapeutical Sciences, Graduate School, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo 113–8519, Japan

Abstract: Mesenchymal cells from various sources are pluripotent and are attractive sources for cell transplantation. In this study, we analyzed recombinant adeno-associated virus (rAAV)-mediated gene expression in human placenta-derived mesenchymal cells (hPDMCs), which reside in placental villi. After transduction of AV-CAG-EGFP, a rAAV expressing enhanced green fluorescence protein (EGFP), hPDMCs showed much higher level of EGFP expression than human umbilical vein endothelial cells or rat aortic smooth muscle cells. The number of EGFP-positive hPDMCs infected by AV-CAG-EGFP alone did not increase significantly by coinfection of adenovirus, which enhanced expression level of the rAAV vector. Moreover, flow cytometric analysis showed discrete positive fraction of EGFP-expressing hPDMCs, which is about 15–20% of the cells infected with AV-CAG-EGFP. Therefore, some cell population in hPDMCs might be highly susceptible to rAAV-mediated gene transduction. In addition, stable EGFP expressions were observed in about 1% of hPDMCs infected with AV-CAG-EGFP at 4 weeks post-infection. Collectively, hPDMCs have characters favorable for rAAV-mediated gene expression.

Key words: Adeno-associated virus, Adenovirus, Placenta, Mesenchymal cell

Bone marrow has been a source of cell transplantation for hematopoietic malignancies. Recently, umbilical cord blood has drawn growing public attention as an efficacious source of hematopoietic stem and progenitor cells in cell transplantation (7, 22). After the establishment of Cord Blood Banks, more than 2,000 cord blood transplantations have been performed throughout the world. In the processing of cord blood, adjacent placenta has been thrown away notwithstanding its possible regenerative capacity, which might be very favorable for tissue regeneration therapy. In a sense, placenta has been left behind in terms of cell therapy. Mesenchymal cells from various sources show pluripotency and are capable of differentiating into osteoblastic or adipocytic lineage under each proper condition (1). In case of placenta, the villous region contains the mesenchymal cell population. Therefore, we focused on human placenta as a source of mesenchymal cells potentially directed towards tissue regenerative therapy (6).

Meanwhile, adeno-associated virus (AAV) has gained attention as a potentially useful vector for human gene therapy mainly by virtue of its safety (11). Although recombinant AAV (rAAV) transduces gene into muscle and neuron efficiently *in vivo*, there are still controversies over using it as a vector for gene transduction into stem cells (19). If rAAV transduces suitable gene efficiently into the pluripotent cell, many therapeutic appli-

Address correspondence to Dr. Takashi Nakaoka, Department of Advanced Medical Science, The Institute of Medical Science, The University of Tokyo, 4–6–1 Shirokanedai, Minato-ku, Tokyo 108–8639, Japan. Fax: +81–3–5449–5456. E-mail: takashin@ims.u-tokyo.ac.jp

Abbreviations: EGFP, enhanced green fluorescence protein; FBS, fetal bovine serum; hPDMCs, human placenta-derived mesenchymal cells; hUVECs, human umbilical vein endothelial cells; kbp, kilobase pairs; PI, propium iodide; rAAV, recombinant adeno-associated virus; rASMCs, rat aortic smooth muscle cells; TU, transducing unit.

cations for cell transplantation would be warranted. It is noteworthy that rAAV stably transduces gene into human neural stem cells (24), although other group reported AAV-mediated transduction into neural progenitor is less efficient (5).

In this study, we examined rAAV-mediated gene transduction into human placenta-derived mesenchymal cells (hPDMCs) and found that hPDMCs is highly susceptible to AAV-mediated gene transduction.

Materials and Methods

Reagents. A plasmid containing AAV genome, pAV1 (8) and 293 embryonic cell lines were obtained from ATCC. Phycoerythrin-conjugated anti-CD34 antibody, phycoerythrin-conjugated anti-CD45 antibody, and propium iodide (PI) were obtained from Becton Dickinson (Mountain View, Calif., U.S.A.). Restriction enzymes were obtained from New England Biolabs, Inc.

Isolation of hPDMC. All placentas were harvested from full-term deliveries (38 to 40 weeks of pregnancy) and cell processings were started within 4 hr of delivery. After removal of the umbilical cord and amnion from the placenta, tissues were cut with scissors and then chopped into sections approximately 1 cm^3 (total weight, 200 to 300 g). The total tissues were washed thoroughly in PBS and then stirred in 330 ml of PBS with 0.05% trypsin and 0.53 mM EDTA at ambient temperature for 10 min. After being filtered through a nylon mesh and added by 15 ml fetal bovine serum (FBS), the fraction containing the released cells were pooled. The sections were digested twice more, and the three fractions were mixed. The cells centrifuged at low speed were suspended in PBS. Following flotation on Ficoll-Hypaque (Amersham), mononuclear cell fraction was isolated and washed in PBS. Then, the collected cells were seeded at a density of 3.0×10^5 cells/cm^2 in DMEM with 10%FBS. Ten days after trypsin digestion, adherent and non-adherent cells were harvested with 1mM EDTA solution. hPDMCs used in this study were within 25 population doubling levels.

Cell cultures. The cells were grown at 37 C under a 95% air and 5% CO_2 atmosphere. Antibiotic-antimycotic (Invitrogen) were added to the all media at 1%, unless otherwise stated. hPDMCs (primary cultures 5, 24 and 26) isolated from three independent placenta donor were used in this study. hPDMCs were maintained in DMEM with 10% FBS and routinely passaged just before reaching confluence by brief exposure to 0.05% trysin and 0.53 mM EDTA at a ratio of 1:8. Human umbilical vein endothelial cells (hUVECs) were grown in EGM-2 with 2% FBS. HeLa and 293 embryonic cell lines were maintained in DMEM with 10% FBS. Rat aortic smooth muscle cells (rASMCs) were prepared from descendeing aorta of 10 wk-old Wistar rats by the explant method and grown in DMEM with 10% FBS (14).

Construction of rAAV carrying the EGFP gene, AV-CA-EGFP. AAV genome was released from pAV1 by restriction with *Bgl*II and cloned into *Bam*HI site of pBluescriptII SK (+). To abolish *Sal*I site, the portion between *Eco*RV and *Nae*I (0.6 kbp) was dissected out and self-ligated to make AV1SK (δRV-Nae). Then, *Sal*I linker (Stratagene) was inserted into blunt-ended *Sna*BI site of AV1SK (δRV-Nae). After the restriction with *Ppu*MI at two sites, a 7.3-kbp fragment was gel purified, blunt-ended and ligated to *Sal*I linker, to generate pAV1SKSalSal (7.1 kbp).

Next, a 0.8-kbp fragment containing open reading frame of EGFP was cut from IRES2-EGFP (Clontech) with *Nco*I and *Hpa*I. Then, the blunt-ended fragment was cloned into pCAGGS, whose *Hind*III site was replaced with *Sal*I to generate pCAGEGFPSal. The pCAGEGFPSal was cut with *Sal*I and the fragment containing the *CMV-IE* enhancer, the chicken β-actin promoter, an intron, the coding region of *EGFP*, and rabbit β-globin polyadenylation signal was ligated to *Sal*I-cut pAV1SKSalSal, which contains a portion of pBluescriptII SK (+) and both ITR region of AAV genome to generate pEGFPAAV. The preservation of ITR structure in the plasmid was checked by restriction pattern with *Ahd*I.

Helper adenovirus-free AAV stock preparation was performed essentially as described (25) and optimized for our system using PTR-UF5 (27), pXX2 and pXX6. The 293 embryonic cell lines were grown on collagen I-coated 150-mm diameter dishes until 80–90% confluence. Then, the media were changed to DMEM with 10% FCS without antibiotics. For each dish, the mixture of 12-μg-pEGFPAAV, 12-μg-pXX2 and 30-μg-pXX6 were transfected into the cells for 6–10 hr using CellPhect Transfection kit (Amersham). Then, media were changed to new DMEM with 10% FBS containing antibiotics and further incubated for 48–60 hr. After aspiration of media, the cells in each dish were suspended in 2.5 ml DMEM, freeze-thawed two times, followed by centrifugation at 1,000×g at 4 C for 10 min. The resultant supernatant was collected and stored at −80 C as AV-CAG-EGFP stock.

To determine transducing unit (TU) of AV-CAG-EGFP, HeLa cells seeded on 2-well glass chamber slides (Lab-Tek II, Nalge Nunc) were infected with several dilutions of AV-CAG-EGFP stock and Ad5dlx at 5 MOI. Forty-eight hr later, the fluorescent cells were counted in a fluorescence microscope. One TU is defined as the vector sufficient to cause visually detectable EGFP expression in one cell.

AAV infection assay. The cells seeded on six-well 36-mm-diameter culture plate were grown until 50–70% confluence. The cells were infected with AV-CAG-EGFP at the indicated concentration in the presence or absence of Ad5dlx at 5 MOI. At the indicated time point after infection, the media containing virus were replaced with fresh media and maintained further. The infected cells were photographed in a fluorescence microscope (Olympus IX70) equipped with external fluorescent system (IX-FLA) or analyzed by flow cytometry in Vantage SE. Dead cells and debris were excluded by PI staining and EGFP expression was measured using a standard filter setup at 525 nm.

Low-molecular-weight DNA from the cell was extracted by a modification of the procedure originally described by Hirt (3, 4). DNA samples were resolved on a 1.2% agarose gel, and transferred to a nylon membrane (Hybond-XL, Amersham). Hybridization was performed with a ^{32}P-labeled fragment containing open reading frame of EGFP (0.8 kbp) using standard technique (18).

Results

The construction of a plasmid, pEGFPAAV, was intended to preserve 165-bp terminal repeat sequence (26). Recombinant AAV expressing EGFP under CAG promoter, AV-CAG-EGFP, was produced by the previously described helper adenovirus-free triple transfection method using pEGFPAAV, pXX-2 and pXX-6 (25). By this method, we routinely obtained 5×10^7–2×10^8 TU/ml of rAAV.

Generally, rAAV-mediated gene expression is augmented by the coinfection of adenovirus as in the case of HeLa cells (Fig. 1) (3). hUVECs and rASMCs were infected with AV-CAG-EGFP at 100 TU/cell in the presence or absence of Ad5dlx, an adenovirus lacking E3 region, at 5 MOI. And then EGFP expression in the cells was examined by a fluorescence microscope. EGFP expression was faintly detectable in the cells at 24 hr post-infection; the intensity increased until 72 hr post-infection. In the presence of Ad5dlx, strong fluorescence was detected in both hUVECs and hPDMCs at 72 hr post-infection (Fig. 1). EGFP expression in rASMCs infected with AV-CAG-EGFP either with or without adenovirus was very low. When the cells were infected with AV-CAG-EGFP in the absence of Ad5dlx, EGFP expression was much stronger in hPDMCs than that in HeLa cells or hUVECs, suggesting rAAV-mediated gene expression in hPDMCs is efficient even in the absence of adenovirus.

To measure the number of EGFP-positive cells, the cells infected with AV-CAG-EGFP were analyzed by flow cytometer. Coinfection with rAAV and Ad5dlx

into hUVECs made the cell population shift rightward in the flow cytometric analysis as compared to the case where hUVECs were infected with rAAV alone (Fig. 2). EGFP-positive hUVECs coinfected with AV-CAG-EGFP and Ad5dlx were twofold of that without Ad5dlx whether AV-CAG-EGFP was used at 100 TU/cell (Fig. 2) or 1,000 TU/cell (data not shown). In contrast, the number of EGFP-positive hPDMCs infected with AV-CAG-EGFP was not significantly different whether infection by AV-CAG-EGFP was performed in the presence or absence of Ad5dlx. In this case, flow cytometric analysis showed discrete positive fraction in hPDMC preparation (Fig. 2). This was a constant feature with three independent hPDMC preparations, although percentage of the positive cells had a range depending on the preparations (Fig. 3A). Therefore, it is likely that some cell populations in hPDMCs are highly susceptible to rAAV-mediated gene transduction. The percentage of EGFP-positive cells increased as the concentration of rAAV employed in the infection increased. This result showed clear dose dependency (Fig. 3B).

Then, hPDMCs were exposed to AV-CAG-EGFP at 100 TU/cell for variable time durations, and EGFP-positive cells were analyzed by flow cytometer at 72 hr post-infection. The percentage of EGFP-positive cells increased with time by the incubation of AV-CAG-EGFP and reached to approximately 11–15% after 4 hr (Fig. 3C). Thus, 4 hr of incubation of hPDMCs with AV-CAG-EGFP is sufficient for sub-optimal gene transduction.

In order to address how long EGFP expression lasts, hPDMCs were exposed to AV-CAG-EGFP at 100 or 1,000 TU/cell in the absence of Ad5dlx for 48 hr, and the cultures were continued up to 4 weeks. The number of EGFP-positive cells decreased at 7 days post-infection as compared to that examined at 72 hr post-infection when fluorescent cells were most abundantly detected (compare Fig. 3B with Fig. 3D). EGFP expression in hPDMCs was brighter with coinfection by Ad5dlx than without coinfection at 72 hr post-infection (Fig. 1). However, at two weeks post-infection, hPDMCs coinfected with AV-CAG-EGFP and Ad5dlx was no brighter than hPDMCs infected with AV-CAG-EGFP alone (data not shown). The number of EGFP-positive cells infected with AV-CAG-EGFP was 0.7% (100 TU/cell) and 1.4% (1,000 TU/cell) at 2 weeks and 0.67% (100 TU/cell) and 1.1% (1,000 TU/cell) at 4 weeks, respectively, showing stable gene expression in about 1% of the cells from 2 weeks through 4 weeks post-infection (Fig. 3D). Over passages of the cells, hPDMCs coinfected with Ad5dlx did not grow well by 2 weeks post-infection and most of them deceased by 4 weeks, possibly due to the effect by amplification of Ad5dlx.

## Ad5dlx(+)   Ad5dlx(-)

Fig. 1. EGFP expression in the cells infected with AV-CAG-EGFP. The cells were seeded onto a 6-well tissue culture plate. hPDMCs (primary culture 26), hUVECs, rASMCs or HeLa cells were infected with AV-CAG-EGFP at 100 TU/cell in the presence (Ad(+)) or the absence (Ad(−)) of Ad5dlx at 5 MOI for 48 hr. Seventy-two hr post-infection, the fluorescent cells were identified through fluorescent microscope and photographed.

Fig. 2. Flow cytometric analysis of EGFP-expressing cells. The cells were seeded onto a 6-well tissue culture plate. hPDMCs (primary culture 26), hUVECs or rASMCs were infected with Ad5dlx at 5 MOI (Ad(+) rAAV(−)), with AV-CAG-EGFP at 100 TU/cell (Ad(−) rAAV(+)) or with both (Ad(+) rAAV(+)). Seventy-two hr post-infection, the cells were subjected to flow cytometric analysis. Percentage of EGFP-positive cells is indicated.

It is widely believed that monomeric replicative form (RFm) of rAAV is intimately involved in rAAV-mediated gene expression (2, 3). Therefore, the Hirt extract was prepared from the cells infected with AV-CAG-EGFP with or without Ad5dlx and the status of rAAV genome was analyzed by southern blotting with ^{32}P-labelled EGFP fragment. Consequently, RFm was found in hUVECs and in hPDMCs infected with AV-CAG-EGFP at 200 TU/cell in the presence of Ad5dlx at 72 hr post-infection (Fig. 4, lanes 2, 4 and 6). Without coinfection by Ad5dlx, RFm was barely detectable in hUVECs or hPDMCs (Fig. 4, lanes 1, 3 and 5). It is noteworthy the bright bands with less electrophoretic mobility than RFm were clearly detected in Hirt extracts from one hPDMC preparation (primary culture 26) infected with

rAAV but not the other hPDMC preparation (primary culture 26) (Fig. 4, lanes 3 through 6). These bands may be derived from dimer and concatemers of rAAV genome. RFm was not found in the extracts from rASMCs, which showed a broad band of single-stranded form (Fig. 4, lane 8).

Discussion

rAAV-mediated gene expression in hPDMCs was far more efficient than that in hUVECs in the absence of helper adenovirus. In our study, rAAV-mediated gene expression in rASMCs was very low in contrast to efficient rAAV-mediated gene expression in human SMCs (10). Difference in terms of the level of gene expression

Fig. 3. AV-CAG-EGFP-mediated EGFP expression in hPDMCs. The cells were seeded onto a 6-well tissue culture plate and infected with AV-CAG-EGFP in the presence (Ad(+)) or the absence (Ad(−)) of Ad5dlx at 5 MOI. The cells were subjected to flow cytometric analysis to determine the percentage of EGFP-positive cells at 72 hr (Panel A through C) or at indicated time (Panel D) post-infection. (A) hPDMCs (primary cultures 5, 24 or 26), hUVECs or rASMCs were infected with AV-CAG-EGFP at 100 TU/cell for 48 hr with or without Ad5dlx. (B) hPDMCs (primary culture 26) were infected with AV-CAG-EGFP at 0, 10, 100, 1,000 TU/cell with or without Ad5dlx. (C) hPDMCs (primary culture 26) were exposed to AV-CAG-EGFP at 100 TU/cell for 0, 1, 4, 12 or 48 hr without Ad5dlx. (D) hPDMCs (primary culture 26) were exposed to AV-CAG-EGFP at 100 or 1000 TU/cell for 48 hr with or without Ad5dlx. The cells, which were maintained for 1 week, 2 weeks or 4 weeks, were subjected to flow cytometric analysis.

is likely to be due to species-dependent susceptibility to rAAV-mediated gene expression (9). Fibroblast growth factor receptor (FGFR) is a receptor for AAV (17). The expression of FGFR in hPDMCs was lower than in hUVECs (data not shown). Cell surface level of heparan sulfate, integrin αVβ5 or other molecules might mediate AAV entry into hPDMCs (20, 21).

Intracellular AAV form is considered to be a primary determinant of rAAV-mediated gene expression. There are still controversies as to the intracellular molecular fate of rAAV genomes (13). In our study, the levels of RFm were greater in hUVECs and hPDMCs co-infected with rAAV and adenovirus than those in the cells infected with rAAV alone at 72 hr post-infection. In both cases, the level of transgene expression in coinfected cells was higher than that in cells infected with rAAV alone. Therefore, our results at least in part agreed with the notion that second-strand synthesis is a crucial step for

efficient rAAV-mediated transduction (2). However, RFm was also found in rASMCs in which rAAV-mediated gene expression was quite low, when the higher titer (1,000 TU/cell) of rAAV was employed for the infection (data not shown). Therefore, RFm might not solely determine AAV-mediated gene expression. It was intriguing that high molecular weight forms of rAAV genome were conspicuous in one hPDMC preparation (primary culture 26) with higher AAV-mediated gene expression, but not in the other hPDMC preparation (primary culture 5) with lower AAV-mediated gene expression. Reportedly, phosphorylation status of cellular FKBP52 protein accounts for rAAV transduction efficiency (16), and topors, a p53 and topoisomerase I binding protein, is involved in this process (23). It might be interesting to examine phosphorylation status of cellular FKBP52 protein in hPDMCs. Other players are also likely to be involved in the efficiency of rAAV-mediated

Fig. 4. Southern blot analysis of Hirt extract. The cells were seeded onto 6-well tissue culture plates. hUVECs (lanes 1 and 2), hPDMCs (primary culture 26, lanes 3 and 4; and primary culture 5, lanes 5 and 6) or rASMCs (lanes 7 and 8) were infected with AV-CAG-EGFP at 200 TU/cell in the presence (lanes 2, 4, 6 and 8) or absence (lanes 1, 3, 5 and 7) of Ad5dlx at 5 MOI. Seventy-two hr post-infection, Hirt extract was prepared from the cells and was subjected to Southern blotting with ^{32}P-labeled EGFP fragment. Thirty out of 50 μl of Hirt extract was loaded onto the gel electrophoresis. The positions of single-stranded form (SS) and monomeric replicative form (RFm) are indicated.

gene expression. It is known that rAAV genome exists in several forms: double-stranded form, episomal concatemer, circular dimer and ones integrated into the host genome, etc. (12). Whether DNA integrated into chromosome accounts for stable gene expression or episomal concatemer still remains to be elucidated.

Our data presented here suggests that some population in hPDMC preparation might be highly susceptible to AAV-mediated gene transduction. We do not know at this moment what molecular marker distinguishes this population from the other cell types in hPDMCs. Isolation of such population should be very important and is currently under way in our laboratory.

Finally, transgene expression lasted up to one month in about 1% of hPDMCs. hPDMCs used in this study represent CD34 (-) and CD45 (-) fraction and show thin myofibrilar shape. hPDMCs also showed reactivity towards SH2, suggesting these cells might have a character of stem cells (15). If transgene expression lasts in stem cells for long, expansion of the cells with transgene expression would be feasible. In case transplantation of hPDMCs would be of therapeutic value in treatment of certain disease, a feature such as easy rAAV-mediated gene expression may further make hPDMC therapy promising.

References

1) Conget, P.A., and Minguell, J.J. 1999. Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J. Cell Physiol. 181: 67–73.

2) Ferrari, F.K., Samulski, T., Shenk, T., and Samulski, R.J. 1996. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70: 3227–3234.

3) Fisher, K.J., Gao, G.P., Weitzman, M.D., DeMatteo, R., Burda, J.F., and Wilson, J.M. 1996. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70: 520–532.

4) Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26: 365–369.

5) Hughes, S.M., Moussavi-Harami, F., Sauter, S.L., and Davidson, B.L. 2002. Viral-mediated gene transfer to mouse primary neural progenitor cells. Mol. Ther. 5: 16–24.

6) Kohnen, G., Kertschanska, S., Demir, R., and Kaufmann, P. 1996. Placental villous stroma as a model system for myofibroblast differentiation. Histochem. Cell Biol. 105: 415–429.

7) Kurtzberg, J., Laughlin, M., Graham, M.L., Smith, C., Olson, J.F., Halperin, E.C., Ciocci, G., Carrier, C., Stevens, C.E., and Rubinstein, P. 1996. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med. 335: 157–166.

8) Laughlin, C.A., Tratschin, J.D., Coon, H., and Carter, B.J. 1983. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene 23: 65–73.

9) Lynch, C.M., Hara, P.S., Leonard, J.C., Williams, J.K., Dean, R.H., and Geary, R.L. 1997. Adeno-associated virus vectors for vascular gene delivery. Circ. Res. 80: 497–505.

10) Maeda, Y., Ikeda, U., Ogasawara, Y., Urabe, M., Takizawa, T., Saito, T., Colosi, P., Kurtzman, G., Shimada, K., and Ozawa, K. 1997. Gene transfer into vascular cells using adeno-associated virus (AAV) vectors. Cardiovasc Res. 35: 514–521.

11) Monahan, P.E., and Samulski, R.J. 2000. AAV vectors: is clinical success on the horizon? Gene Ther. 7: 24–30.

12) Nakai, H., Storm, T.A., and Kay, M.A. 2000. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74: 9451–9463.

13) Nakai, H., Yant, S.R., Storm, T.A., Fuess, S., Meuse, L., and Kay, M.A. 2001. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75: 6969–6976.

14) Nakaoka, T., Gonda, K., Ogita, T., Otawara-Hamamoto, Y., Okabe, F., Kira, Y., Harii, K., Miyazono, K., Takuwa, Y., and Fujita, T. 1997. Inhibition of rat vascular smooth muscle proliferation *in vitro* and *in vivo* by bone morphogenetic protein-2. J. Clin. Invest. **100**: 2824–2832.

15) Pittenger, M.F., Mackay, A.M., Beck, S.C., Jaiswal, R.K., Douglas, R., Mosca, J.D., Moorman, M.A., Simonetti, D.W., Craig, S., and Marshak, D.R. 1999. Multilineage potential of adult human mesenchymal stem cells. Science **284**: 143–147.

16) Qing, K., Hansen, J., Weigel-Kelley, K.A., Tan, M., Zhou, S., and Srivastava, A. 2001. Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J. Virol. **75**: 8968–8976.

17) Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., and Srivastava, A. 1999. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. **5**: 71–77.

18) Sambrook, J., and Russell, D.W. 2001. Molecular cloning, A laboratory manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York.

19) Srivastava, A. 2002. Obstacles to human hematopoietic stem cell transduction by recombinant adeno-associated virus 2 vectors. J. Cell Biochem. **Suppl**: 39–45.

20) Summerford, C., and Samulski, R.J. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. **72**: 1438–1445.

21) Summerford, C., Bartlett, J.S., and Samulski, R.J. 1999. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. **5**: 78–82.

22) Wagner, J.E., Kernan, N.A., Steinbuch, M., Broxmeyer, H.E., and Gluckman, E. 1995. Allogeneic sibling umbilical-cord-blood transplantation in children with malignant and non-malignant disease. Lancet **346**: 214–219.

23) Weger, S., Hammer, E., and Heilbronn, R. 2002. Topors, a p53 and topoisomerase I binding protein, interacts with the adeno-associated virus (AAV-2) Rep78/68 proteins and enhances AAV-2 gene expression. J. Gen. Virol. **83**: 511–516.

24) Wu, P., Ye, Y., and Svendsen, C.N. 2002. Transduction of human neural progenitor cells using recombinant adeno-associated viral vectors. Gene Ther. **9**: 245–255.

25) Xiao, X., Li, J., and Samulski, R.J. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. **72**: 2224–2232.

26) Xiao, X., Xiao, W., Li, J., and Samulski, R.J. 1997. A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle. J. Virol. **71**: 941–948.

27) Zolotukhin, S., Potter, M., Hauswirth, W.W., Guy, J., and Muzyczka, N. 1996. A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. J. Virol. **70**: 4646–4654.

Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells

Katsuaki Sato, Naohide Yamashita, Masanori Baba, and Takami Matsuyama

To exploit a novel strategy to regulate T cell–mediated immunity, we established human and murine modified dendritic cells (DCs) with potent immunoregulatory properties (designed as regulatory DCs), which displayed moderately high expression levels of major histocompatibility complex (MHC) molecules and extremely low levels of costimulatory molecules compared with their normal counterparts. Unlike human normal DCs, which caused the activation of allogeneic CD4+ and CD8+ T cells, human regulatory DCs not only induced their anergic state but also generated CD4+ or CD8+ regulatory T (Tr) cells from their respective naive subsets in vitro. Although murine normal DCs activated human xenoreactive T cells in vitro, murine regulatory DCs induced their hyporesponsiveness. Furthermore, transplantation of the primed human T cells with murine normal DCs into severe combined immunodeficient (SCID) mice enhanced the lethality caused by xenogeneic graft-versus-host disease (XGVHD), whereas transplantation of the primed human T cells with murine regulatory DCs impaired their ability to cause XGVHD. In addition, a single injection of murine regulatory DCs following xenogeneic or allogeneic transplantation protected the recipients from the lethality caused by XGVHD as well as allogeneic acute GVHD. Thus, the modulation of T cell–mediated immunity by regulatory DCs provides a novel therapeutic approach for immunopathogenic diseases. (Blood. 2003;101:3581-3589)

© 2003 by The American Society of Hematology

Introduction

Dendritic cells (DCs) are unique professional major antigen (Ag)–presenting cells (APCs) capable of stimulating naive T cells in the primary immune response and are more potent APCs than monocytes/macrophages or B cells.[1]

The treatment of normal immature DCs (iDCs) with interleukin 10 (IL-10) caused a down-regulation in the expressions of major histocompatibility complex (MHC) and costimulatory molecules, leading to a suppression of their T cell–stimulatory ability[2] as well as an induction of anergic T cells.[3,4] Recently, repetitive stimulation of human naive CD4+ T cells with allogeneic normal iDCs not only induced T-cell anergy but also generated CD4+CD25+CD152+ regulatory T (Tr) cells from their naive subsets.[5] Furthermore, a single injection of antigenic peptide-pulsed normal iDCs led to an appearance of Ag-specific IL-10–producing CD8+ T cells in healthy individuals.[6] However, the clinical application of self Ag-pulsed or allogeneic/xenogeneic normal iDCs may not be suitable for the treatment of autoimmune diseases or for allogeneic/xenogeneic organ transplantation because the injected normal iDCs are not likely to remain immature in vivo after recirculation and home into the damaged tissue where chronic inflammation is always present.[7] Therefore, further development of DCs with potent negative regulatory ability for T cells is thought to facilitate their use for the prevention and the treatment of immunopathogenic diseases.

To exploit a novel strategy involving the use of DCs for the regulation of T cell–mediated immunity, we examined the effect of human and murine modified DCs with potent immunoregulatory properties (designed as regulatory DCs) on allogeneic/xenogeneic T-cell responses in vivo and in vitro.

Materials and methods

Mice, media, and reagents

Female BALB/c mice (H-2^d, 4-6 weeks of age) and C57/BL6 mice (H-2^b, 4-6 weeks of age) were purchased from Charles River Laboratories (Raleigh, NC). Female C.B.-17-scid (severe combined immunodeficient; SCID) mice (H-2^d, 4-6 weeks of age) were purchased from Clea Japan (Tokyo, Japan). They were maintained according to institutional guidelines under approved protocols in the Institute of Laboratory Animal Science (School of Medicine, Kagoshima University, Japan). Human granulocyte-macrophage colony-stimulating factor (GM-CSF), human IL-2, human IL-4, human IL-10, human tumor necrosis factor α (TNF-α), human transforming growth factor β1 (TGF-β1), murine GM-CSF, and murine IL-10 were purchased from Pepro Tech (London, United Kingdom). The medium used throughout was RPMI 1640 (for T cells and DCs; Sigma, St Louis, MO) or Dulbecco modified Eagle medium (DMEM; for fibroblasts; Sigma) supplemented with an antibiotic-antimycotic (Gibco BRL, Rockville, MD) and 10% heat-inactivated fetal calf serum (FCS; Gibco).

Cell preparations

Peripheral blood mononuclear cells (PBMCs) obtained from 20 healthy volunteers were resuspended in culture medium and allowed to adhere to the tissue-culture dish (Becton Dickinson, Franklin Lakes, NJ). After 2 hours at 37°C, nonadherent cells were removed by a vigorous washing and adherent cells (> 90% CD14+ cells) were used as monocytes. Monocytes were cultured with human GM-CSF (50 ng/mL) and human IL-4 (50 ng/mL) for 7 days.[2,4] Following this procedure, nonadherent cells were collected and subjected to the negative selection with anti-CD2 monoclonal antibody (mAb)–conjugated immunomagnetic beads (Dynal, Oslo, Norway) and anti-CD19 mAb-conjugated immunomagnetic beads (Dynal) to deplete CD2+ cells (T cells and natural killer [NK] cells) and CD19+ cells (B cells). The resultant cells were used as normal iDCs. Similarly, human modified/regulatory iDCs were also generated from monocytes cultured with human GM-CSF (50 ng/mL), human IL-4 (50 ng/mL), human IL-10, and human TGF-β1 (each 50 ng/mL) for 7 days. Human IL-10–treated iDCs were prepared from the culture of normal iDCs with human IL-10 (50 ng/mL) for 3 days.[4] These cells were washed 3 times with cold phosphate-buffered saline (PBS) after the generation to prevent carryover of cytokines, and were cultured with human TNF-α (50 ng/mL) in the tissue-culture dish for another 3 days for the preparation of mature DCs (mDCs). These DC preparations were typically more than 95% pure as indicated by anti–HLA-DR mAb (BD Pharmingen, San Diego, CA) staining, and contained less than 0.1% T cells, B cells, monocytes/macrophages, and NK cells as assessed by fluorescence-activated cell sorting (FACS) analysis (Becton Dickinson, Mountain View, CA).

The generation of murine normal DCs was performed according to the previous report[8] with some modifications. Briefly, bone marrow (BM) cells (BALB/c mice) were cultured with murine GM-CSF (20 ng/mL) in a bacteriologic Petri dish (BIO-BIK, Tokyo, Japan) for 6 days. Nonadherent cells were collected and subjected to the negative selection with mAbs to Ly-76, CD2, B220, CD14, and Ly-6G (all from BD Pharmingen) plus sheep antirat IgG mAb-conjugated immunomagnetic beads (Dynal). The resultant cells were washed 3 times with cold PBS after the generation to prevent carryover of cytokines and stimulated with lipopolysaccharide (1 μg/mL; Sigma) in a bacteriologic Petri dish for 2 days. Similarly, murine modified/regulatory DCs were also obtained by culturing BM cells with murine GM-CSF (20 ng/mL), murine IL-10 (20 ng/mL), and human TGF-β1 (20 ng/mL) for 6 days followed by lipopolysaccharide (1 μg/mL) for 2 days. These DC preparations were typically more than 90% pure as indicated by anti–I-A/I-E mAb (BD Pharmingen) staining, and contained less than 0.1% erythrocytes, T cells, B cells, monocytes/macrophages, NK cells, and neutrophils as assessed by FACS analysis.

Human skin fibroblasts were prepared from epidermal skin tissues after obtaining informed consent from 2 different healthy volunteers.

Human total T cells were purified from PBMCs obtained from 20 healthy volunteers with a T-cell negative isolation kit (Dynal).[9] Subsequently, naive CD4+ or CD8+ T cells were negatively selected from total T cells with anti-CD8 mAb or anti-CD4 mAb (each from BD Pharmingen) in combination with anti-CD45RO mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads (Dynal). These T-cell preparations were typically more than 98% pure as indicated by FACS analysis. For preparation of human Ag-specific CD8+ T cells, PBMCs were cocultured with irradiated (15 Gy from a ^{137}Cs source, MBR-1505R2, Hitachi Medical, Tokyo, Japan) allogeneic fibroblasts derived from an unrelated donor (donor no. 1) in the presence of human IL-2 (100 U/mL) for 2 weeks,[4] and CD8+ T cells were positively selected with a CD8+ isolation kit (Dynal) from the coculture.

Flow cytometry

Cells were stained with the following mAbs to human and murine markers: CD1a and CD83 (Coulter Immunology, Hialeah, FL); CD3, CD11c, CD25, CD28, CD40, CD45, CD80, CD86, CD152, CD154, HLA-A/B/C, I-K[d], and isotype-matched control mAb (all from BD Pharmingen); and anti–E-cadherin (E-cad) mAb (Chemicon Interna-

tional, Temecula, CA).[2,4] For analysis of the intracellular expression of cytokines,[4] permeabilized/fixed cells were stained with mAbs to human IL-2, IL-4, IL-10, and interferon γ (IFN-γ; all from BD Pharmingen) following stimulation with plate-bound antihuman CD3 mAb (10 μg/mL; BD Pharmingen) plus soluble antihuman CD28 mAb (10 μg/mL; BD Pharmingen; for CD4+ T cells) or phorbol myristate acetate (PMA; 20 ng/mL; Sigma) plus Ca2+ ionophore A23187 (500 ng/mL; Sigma; for CD8+ T cells) for 6 hours. Fluorescence staining was analyzed with a FACScan flow cytometer and CellQuest software (Becton Dickinson, Mountain View, CA), and data are expressed as mean fluorescence intensity (MFI).

Allogeneic/xenogeneic priming of human T cells in vitro

Human naive CD4+ T cells or Ag-specific CD8+ T cells (5 × 10⁶) were primed with irradiated (15 Gy) human allogeneic DCs (5 × 10³ to 5 × 10⁵) for 3 days, and these T-cell subsets were negatively selected with antihuman CD11c mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads. These T-cell preparations contained less than 0.1% CD11c+ cells as assessed by FACS analysis. For in vitro xenogeneic priming, human T cells (5 × 10⁷) were primed with irradiated (15 Gy) murine DCs (5 × 10⁶, H-2ᵈ) in the presence or absence of human IL-2 (100 U/mL) for 3 days. After incubation, human T cells were negatively selected with anti–I-Kᵈ mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads. These T-cell preparations contained less than 0.1% I-Kᵈ+ cells as assessed by FACS analysis. Cells were rested in medium containing human IL-2 (10 U/mL) for 3 days before use.

Mixed leukocyte reaction

Human T-cell subsets (10⁵) were cultured in 96-well plates (Costar, Cambridge, MA) with various numbers of irradiated (15 Gy) allogeneic/ xenogeneic DCs in the presence or absence of human IL-2 (100 U/mL). Thymidine incorporation was measured as counts per minute (cpm) for the indicated days after an 18-hour pulse with [³H]-thymidine.[2,4]

Cytotoxic T-lymphocyte assay

Ag-specific CD8+ T cells (5 × 10⁵) were cultured with Na₂[51]CrO₄ (100 μCi/10⁶ cells [3.7 MBq]; NEN Life Science Products, Boston, MA)– labeled allogeneic fibroblasts derived from 2 different donors (10⁴) for 4 hours. The supernatants were harvested, the radioactivity (cpm) was measured, and the percentage of specific lysis was calculated.[4]

Preparation of Tr-cell subsets

Human CD4+CD45RA+ T cells (5 × 10⁶) were cultured with irradiated (15 Gy) allogeneic normal mDCs (5 × 10⁵) for 3 days, and Ag-primed CD4+ T cells were obtained from the coculture by the depletion of DCs as described in "Allogeneic/xenogeneic priming of human T cells in vitro." Human CD4+CD45RA+ T cells (5 × 10⁶) were also cultured with irradiated (15 Gy) allogeneic regulatory iDCs (5 × 10⁵) for 5 days, and T cells were negatively selected by the depletion of DCs. CD4+CD25+ T cells or CD4+CD25− T cells were then selected with anti-CD25 mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads, and they were typically more than 95% pure as indicated by FACS analysis.

Human naive CD8+ T cells (5 × 10⁶) were cocultured with allogeneic normal mDCs (5 × 10⁵) or regulatory iDCs (5 × 10⁵) for 5 days, and CD8+ T cells were negatively selected by the depletion of DCs. Subsequently, CD8+CD28+ T cells or CD8+CD28− T cells were selected using antihuman CD28 mAb (BD Pharmingen) plus goat antimouse IgG mAb-conjugated immunomagnetic beads.

The removal of the immunomagnetic beads from the selected cells was performed by competitive detachment with mouse serum for 4 hours, and they rested in medium for 16 hours according to the manufacturer's instruction manual. After incubation, the residual immunomagnetic beads were removed by the magnetic particle concentrator (MPC-S, Dynal).

Analysis of Tr-cell function

Ag-primed CD4$^+$ T cells or CD4$^+$CD25$^+$ T cells (10^5) were cultured with irradiated (15 Gy) allogeneic normal mDCs (10^4) in the presence or absence of different numbers of CD4$^+$CD25$^+$ T cells or Ag-primed CD4$^+$ T cells in 96-well plates. In another experiment, Ag-primed CD4$^+$ T cells (10^5) were cultured with irradiated (15 Gy) allogeneic normal mDCs (10^4) in the presence or absence of different numbers of CD8$^+$CD28$^+$ T cells or CD8$^+$CD28$^-$ T cells in 96-well plates. The proliferative response of T cells was evaluated on day 5 by [^{3}H]-thymidine incorporation. Alternatively, human CD8$^+$CD28$^+$ T cells or CD8$^+$CD28$^-$ T cells (10^6) plus irradiated (15 Gy) allogeneic normal mDCs (10^5) were either added directly to the coculture of Ag-primed CD4$^+$ T cells (10^6) with irradiated (15 Gy) allogeneic normal mDCs (10^5) in 24-well plates (Costar) or were placed separately in 24-well Transwell cell culture chambers (Millicell, 0.4-μm pore size; Millipore, Bedford, MA) in the same well for 4 days. Following depletion of DCs, total T cells (10^5/well) were transferred to 96-well plates. The proliferative response was measured after an additional 18-hour pulse with [^{3}H]-thymidine.

A model of XGVHD in SCID mice engrafted with human peripheral blood lymphocytes and murine allogeneic acute GVHD

For xenogeneic transplantation, SCID mice (5 animals in each group) were pretreated 1 day prior to the transplantation with a single dose (lyophilized Ab was resuspended in 1 mL PBS, and 20 μL/mouse was given by intraperitoneal injection) of anti-asialo GM1 antiserum (the protein concentration was 10 mg/mL, WAKO, Osaka, Japan).[10] Immediately prior to the transplantation, SCID mice were exposed to a sublethal total body irradiation (5 Gy/mouse).[10] Subsequently, unprimed human T cells or xenogeneic primed human T cells prepared as described (4 × 10^7/mouse) were intravenously injected into SCID mice under sterile conditions. For murine allogeneic transplantation, SCID mice received a lethal total body irradiation (10 Gy/mouse), and the recipients were injected with BM cells (H-2^b, 2 × 10^7/mouse) plus spleen mononuclear cells (H-2^b, 2 × 10^7/mouse). In a parallel experiment, SCID mice engrafted with human peripheral blood lymphocytes (hu-PBL-SCID mice; 5 animals in each group) or SCID mice underwent allogeneic transplantation (5 animals in each group), receiving a single intravenous injection of murine normal or modified/regulatory DCs (4 × 10^6/mouse) 2 days after allogeneic/xenogeneic transplantation. Alternatively, intravenous injections of human IL-2 (10^4 U/mouse) were performed on days 3, 5, and 7 after xenogeneic transplantation in hu-PBL-SCID mice receiving murine modified/regulatory DCs (5 animals in each group). Recipients were monitored once every day from the day of transplantation until they died naturally of xenogeneic graft-versus-host disease (XGVHD), and the survival (%) was calculated as a function of time. In another experiment, hu-PBL-SCID mice (5 animals in each group) were killed on day 10 after xenogeneic transplantation to obtain spleen tissue. Spleen mononuclear cells were obtained by centrifugation with the use of Histopaque-1080 (Sigma), and the interphase fraction was recovered. The engraftment of human T cells in spleen in hu-PBL-SCID mice was then accessed by FACS analysis with mAbs to human CD3 and CD45. Transplanted human T cells were also negatively selected from spleen mononuclear cells with anti-I-K^d mAb plus goat antimouse IgG mAb-conjugated immunomagnetic beads. Cells were rested in medium containing human IL-2 (10 U/mL) before use.

Statistical analysis

Data are expressed as mean values ± SD of all individual experiments. All analyses for statistically significant differences were performed with the Student paired t test or Mann-Whitney U test. $P < .01$ was considered significant.

Results

Human modified DCs act as regulatory DCs to induce T-cell anergy

Modified iDCs expressed both the DC-marker (CD1a and CD11c) and the Langerhans cell marker (E-cad), but not the monocyte/macrophage-marker (CD14) as shown in Figure 1A. On the other hand, they showed moderately high expression levels of MHC molecules (HLA-A/B/C and HLA-DR), whereas they exhibited extremely low levels of costimulatory molecules (CD40, CD80, and CD86) as compared with normal iDCs (Figure 1B-D). On stimulation with TNF-α, CD83 was detected, whereas the DC and the Langerhans cell markers were down-regulated (Figure 1A). In addition, the expression levels of MHC and costimulatory molecules were changed to various degrees following this stimulation (Figure 1B-D). We also observed that modified DCs were less effective for the activation of allogeneic CD4$^+$ T cells than normal DCs and IL-10–treated iDCs (Figure 2A-B).

We examined the ability of allogeneic modified DCs to induce T-cell anergy. The primed naive CD4$^+$ T cells with allogeneic normal DCs showed vigorous response to the same donor-derived normal mDCs (Figure 2A). In contrast, the primed naive CD4$^+$ T cells with allogeneic-modified DCs were hyporesponsive to further stimulation with the same donor-derived normal mDCs, and the addition of IL-2 to a second culture partly enhanced this response (Figure 2A). Similar results were observed when total CD4$^+$ T cells were used as the responder cells, and the degree of modified DC-induced T-cell hyporesponsiveness was higher than that of IL-10–treated iDCs (Figure 2B).

Furthermore, allogeneic modified DCs induced anergic CD4$^+$ T cells in a dose-dependent manner (Figure 2C), and they retained the hyporesponsiveness at least for 2 weeks (Figure 2D). In addition, the primed CD4$^+$ T cells with allogeneic-modified DCs exhibited a weaker response to the unrelated donor-derived allogeneic normal mDCs in a second culture than those primed with allogeneic normal DCs (Figure 2A).

We also examined the effect of modified DCs on allogeneic normal mDC-mediated activation of allogeneic CD4$^+$ T cells (Figure 2E). The addition of allogeneic normal mDCs, but not normal iDCs, to the coculture of Ag-primed CD4$^+$ T cells with normal mDCs slightly enhanced their response, whereas allogeneic-modified DCs significantly suppressed this response in a dose-dependent manner.

We further tested the effect of allogeneic-modified DCs on cytotoxic T-lymphocyte (CTL) activity of Ag-specific CD8$^+$ T cells (Figures 2F). These CD8$^+$ T cells showed cytotoxicity only against allogeneic fibroblasts (donor no. 1) used in their generation, indicating that their cytotoxicity was Ag specific. Stimulation with allogeneic normal mDCs, but not normal iDCs, enhanced their CTL activity, whereas treatment with allogeneic-modified DCs suppressed it in a dose-dependent manner. Furthermore, little or no change in CTL activity was observed when they were treated with allogeneic DCs derived from unrelated donor (donor no. 2) to allogeneic fibroblasts used in their generation, indicating that their regulations were Ag specific. Similar results were observed in other allogeneic combinations (data not shown).

Collectively, human modified DCs were potent regulators for alloreactive effector T cells, and we referred to modified DCs as regulatory DCs.

A

CD1a   CD14   CD11c   CD83   E-cad

normal iDCs

modified iDCs

normal mDCs

modified mDCs

Relative Cell Number

Fluorescence Intensity

B

CD40   CD80   CD86   HLA-A/B/C   HLA-DR

normal iDCs

modified iDCs

normal mDCs

modified mDCs

Relative Cell Number

Fluorescence Intensity

C

normal iDCs

normal mDCs

modified iDCs

modified mDCs

IL-10-treated iDCs

□ CD40
□ CD80
▨ CD86
■ HLA-A/B/C
■ HLA-DR

% positive cells

D

CD40

normal iDCs
normal mDCs
modified iDCs
modified mDCs
IL-10-treated iDCs

MFI

HLA-A/B/C

normal iDCs
normal mDCs
modified iDCs
modified mDCs
IL-10-treated iDCs

MFI

CD80

normal iDCs
normal mDCs
modified iDCs
modified mDCs
IL-10-treated iDCs

MFI

HLA-DR

normal iDCs
normal mDCs
modified iDCs
modified mDCs
IL-10-treated iDCs

MFI

CD86

normal iDCs
normal mDCs
modified iDCs
modified mDCs
IL-10-treated iDCs

MFI

Figure 1. Phenotypic profile of human modified DCs. (A-B) Cells were stained with the stated mAbs against markers for the DC family molecules (A) and MHC and costimulatory molecules (B) or isotype-matched mAbs, and cell surface expression was analyzed by FACS. Data are represented by a histogram in which cells were stained with the stated mAbs (thick lines) or isotype-matched mAbs (thin lines). The values shown in the flow cytometry profiles are MFI. The results are representative of 10 experiments with similar results. (C) The percent positive cells for MHC and costimulatory molecules were expressed as mean values ± SD of 10 individual experiments. *P < .01 compared with the respective iDCs by Student paired t test. (D) The expression levels of MHC and costimulatory molecules were expressed as MFI ± SD of 10 individual experiments. *P < .01 compared with the respective iDCs or among groups by Student paired t test.

Human regulatory DCs induce CD4+CD25+ Tr cells

CD4+CD25+ T cells reportedly act as Tr cells to suppress the responses of alloreactive or self-reactive CD4+ T cells in an Ag-nonspecific manner, and this T-cell subpopulation is supposed to maintain immunologic self-tolerance or control autoimmunity.[11-13] A single stimulation with allogeneic regulatory DCs predominantly generated CD4+CD25+ and CD4+CD152+ T cells from naive CD4+ T cells, whereas allogeneic normal DCs induced CD4+CD25+ and CD4+CD154+ T cells (Figure 3A). We also observed that a large proportion of CD4+CD25+ T cells expressed CD152 (data not shown). On the other hand, IL-10–producing CD4+ T cells were increased in the primed CD4+ T cells with allogeneic regulatory DCs, whereas IFN-γ– and IL-2–producing CD4+ T cells were increased in the primed CD4+ T cells with allogeneic normal DCs as compared with unprimed CD4+ T cells (Figure 3B).

To examine the function of CD4+CD25+ T cells generated from the primed naive CD4+ T cells with allogeneic regulatory iDCs, we examined their effect on allogeneic normal mDC-induced activation of Ag-primed CD4+ T cells (Figure 3C). Ag-primed CD4+ T cells vigorously responded to allogeneic normal mDCs, whereas CD4+CD25+ T cells exhibited a poor response. In addition, CD4+CD25+ T cells suppressed the response of Ag-primed CD4+ T cells to allogeneic normal mDCs in a dose-dependent manner. However, we did not observe a dose-response relationship in which Ag-primed CD4+ T cells overcame the suppressive effect of CD4+CD25+ T cells when CD4+CD25+ T cells were cultured with allogeneic normal mDCs in the presence of increasing numbers of Ag-primed CD4+ T cells, indicating that this suppressive effect may not be due to their simple competition for allogeneic normal mDCs. We also observed that the separation of CD4+CD25+ T cells and Ag-primed CD4+ T cells abolished their inhibitory effect,

Figure 2. Human regulatory DCs induce T-cell anergy in alloreactive T cells. (A) Human naive CD4+ T cells (10⁵) were cultured with allogeneic normal or modified DCs (10⁴), and the proliferative response was measured on day 5. In another experiment, human naive CD4+ T cells (5 × 10⁶) were cultured with allogeneic normal or modified DCs (5 × 10⁵) for 3 days. These CD4+ T cells were then rescued, and cells (10⁵) were subsequently restimulated with allogeneic normal mDCs (10⁴) generated from same donor or unrelated donor in the presence or absence of human IL-2 in a second coculture. The proliferative response was measured on day 5. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with CD4+ T cells plus allogeneic normal mDCs under each set of experimental conditions by Student paired *t* test. (B) Human total CD4+ T cells (10⁵) were cultured with the indicated types of allogeneic DCs (10⁴), and the proliferative response was measured on day 5. In another experiment, human total CD4+ T cells (5 × 10⁶) were cultured with the indicated types of allogeneic DCs (5 × 10⁵) for 3 days. These CD4+ T cells were then rescued, cells (10⁵) were subsequently restimulated with allogeneic normal mDCs (10⁴) generated from same donor in a second coculture, and the proliferative response was measured on day 5. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with CD4+ T cells plus allogeneic normal mDCs under each set of experimental conditions by Student paired *t* test. (C) Human naive CD4+ T cells (10⁵) were cultured with allogeneic normal or modified DCs (10³-10⁴), and the proliferative response was measured on day 5. In another experiment, human naive CD4+ T cells (5 × 10⁶) were cultured with allogeneic normal or modified DCs (5 × 10⁴ to 5 × 10⁵) for 3 days. These CD4+ T cells were then rescued, and cells (10⁵) were subsequently restimulated with allogeneic normal mDCs (10⁴) generated from same donor in a second coculture. The proliferative response was measured on day 5. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with CD4+ T cells plus allogeneic normal mDCs under each set of experimental conditions by Student paired *t* test. (D) Human naive CD4+ T cells (5 × 10⁶) were cultured with allogeneic normal or modified DCs (5 × 10⁵) for 3 days. These CD4+ T cells were then rescued, and cells (10⁵) were subsequently restimulated with allogeneic normal mDCs (10⁴) generated from same donor. The proliferative response was measured on the indicated days. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with CD4+ T cells plus allogeneic normal mDCs by Student paired *t* test. (E) Human naive CD4+ T cells (10⁵) were cultured with allogeneic normal mDCs (10⁴), and the proliferative response was measured on day 5. In another experiment, human naive CD4+ T cells (5 × 10⁶) were cultured with allogeneic normal mDCs (5 × 10⁵) for 3 days. These CD4+ T cells were then rescued, and cells (10⁵) were subsequently cultured in medium alone (none) or restimulated with allogeneic normal mDCs (10⁴) in the presence or absence of allogeneic normal or modified DCs (10³-10⁴) in a second coculture. The proliferative response was measured on day 5. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with Ag-primed CD4+ T cells plus allogeneic normal mDCs in second coculture by Student paired *t* test. (F) Human allogeneic Ag-specific CD8+ T cells (5 × 10⁶), which were obtained from the primed PBMCs with allogeneic fibroblasts (donor no. 1), were cocultured with or without allogeneic normal or modified DCs (5 × 10³ to 5 × 10⁵) derived from the indicated donors (no. 1 or 2) for 3 days. These CD8+ T cells were then rescued, and cells (5 × 10⁵) were subsequently subjected to a cytotoxicity assay against the allogeneic fibroblasts (10⁴) derived from the indicated donors (no. 1 or 2). The value of spontaneous release cpm was less than 10% of the total release cpm. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with allogeneic Ag-specific CD8+ T cells alone by Student paired *t* test.

and the addition of IL-2 restored the response of Ag-primed CD4+ T cells at least partially, whereas neutralizing Abs against IL-10 or TGF-β did not reverse their inhibitory effect (data not shown). In addition, CD4+CD25+ T cells showed a more potent inhibitory effect on the response of naive CD4+ T cells to allogeneic normal mDCs than that of naive CD4+ T cells to other donor-derived allogeneic normal mDCs by approximately 2-fold (data not shown), indicating that CD4+CD25+ T cells cause Ag-specific and

A   **B**   **C**

Figure 3. Characterization of CD4+CD25+ T cells generated from the primed human naive CD4+ T cells with allogeneic regulatory DCs. (A-B) Human allogeneic naive CD4+ T cells (5 × 10⁶) were cultured with allogeneic normal or regulatory DCs (5 × 10⁵) for 5 days, and CD4+ T cells isolated from the coculture were assayed for phenotype (A) and cytokine profile (B) by FACS. The results are representative of 5 experiments with similar results, and data are represented by a dot plot. (C) Human Ag-primed CD4+ T cells were isolated from the coculture of human naive CD4+ T cells (5 × 10⁶) with allogeneic normal mDCs (5 × 10⁵) for 3 days. CD4+CD25+ T cells were isolated from the coculture of human naive CD4+ T cells (5 × 10⁶) with allogeneic regulatory iDCs (5 × 10⁵) for 5 days. Human Ag-primed CD4+ T cells or CD4+CD25+ T cells (10⁵) were cultured with allogeneic normal mDCs (10⁴) in the presence or absence of different numbers of CD4+CD25+ T cells or Ag-primed CD4+ T cells, and the proliferative response was measured on day 5. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with Ag-primed CD4+ T cells plus allogeneic normal mDCs by Student paired t test. Error bars express SD of mean values.

Ag-nonspecific suppressions. These results indicate that regulatory DCs could efficiently generate CD4+CD25+ Tr cells from naive CD4+ T cells.

Human regulatory DCs induce CD8+CD28⁻ Tr cells

Serial stimulations of human naive CD8+ T cells with allogeneic/xenogeneic APCs reportedly induced the generation of IFN-γ–producing CD8+CD28⁻ Tr cells regulating the response of CD4+ T cells.[14-16] On the other hand, a single injection of antigenic peptide-pulsed normal iDCs into humans induced peptide-specific CD8+ T cells producing IL-10.[6] The coculture of naive CD8+ T cells with allogeneic regulatory DCs induced CD8+ CD28⁻ T cells, whereas allogeneic normal DCs preferentially generated CD8+CD28+ T cells (Figure 4A). In addition, IL-10–producing CD8+ T cells were increased in the primed CD8+ T cells with allogeneic regulatory DCs, whereas IFN-γ–producing CD8+ T cells were increased in the primed CD8+ T cells with allogeneic normal mDCs as compared with unprimed CD8+ T cells (Figure 4A).

We also examined the effect of CD8+CD28⁻ T cells generated from the primed naive CD8+ T cells with allogeneic regulatory iDCs on the allogeneic response of Ag-primed CD4+ T cells (Figure 4B). CD8+CD28+ T cells generated from the primed naive CD8+ T cells with allogeneic normal mDCs showed a response to allogeneic normal mDCs. In contrast, CD8+CD28⁻ T cells not only showed a poor response to allogeneic normal mDCs but also suppressed the response of Ag-primed CD4+ T cells to allogeneic normal mDCs in a dose-dependent manner. Furthermore, this suppressive effect was abrogated when the 2 cell populations were separated. We also observed that CD8+CD28+ T cells generated from the primed naive CD8+ T cells with allogeneic regulatory iDCs showed a poor response to allogeneic normal mDCs, whereas they did not show the suppressive effect (data not shown). These results indicate that regulatory DCs could generate CD8+CD28⁻ Tr cells from naive CD8+ T cells.

Impairment of xenogeneic response of human T cells by murine regulatory DCs

There is increasing interest in xenogeneic organ transplantation in a clinical setting, and the suppression of human xenoreactive T cells is thought to be crucial for xenogeneic organ transplantation. To test whether regulatory DCs can regulate xenoreactive T cells, we generated modified DCs from murine BM cells (H-2ᵈ). In contrast to murine normal DCs, murine modified DCs showed moderately high expression levels of the DC marker (CD11c) and MHC molecules (I-Kᵈ and I-A/I-E), whereas they exhibited extremely low levels of costimulatory molecules (CD40, CD80, CD86; Figure 5A). Furthermore, murine modified DCs showed poor activation of human T cells as compared with murine normal DCs (data not shown). In addition, the primed human T cells with murine normal DCs (H-2ᵈ) responded to restimulation with murine normal mDCs (H-2ᵈ), whereas the primed human T cells with murine modified DCs failed to respond to this stimulation (data not shown), indicating that murine modified DCs also act as regulatory DCs to induce an anergy in human xenoreactive T cells.

The preventive effect of a group of DCs on T cell–mediated immunopathogenic diseases via an induction of T-cell anergy remains unknown. The hu-PBL-SCID mice (H-2ᵈ) reportedly showed a lethal XGVHD, and the depletion of human CD4+ T cells abrogated this pathogenesis.[10] To evaluate the inhibitory effect of regulatory DCs on T cell–mediated immunopathogenesis in vivo, we examined the ability of the primed human T cells with murine regulatory DCs to induce XGVHD in hu-PBL-SCID mice (Figure 5B). All hu-PBL-SCID mice (control group) died of XGVHD within 24 days following transplantation. In these mice, clinical symptoms of XGVHD, such as hair ruffling, lower mobility, and weight loss became apparent within 15 days. Transplantation with the primed human T cells with murine normal DCs enhanced the incidence of XGVHD, and this treatment reduced the life span of these engrafted mice as compared with the control group (P < .01). In contrast, the incidence of XGVHD was significantly reduced in SCID mice receiving transplants of the primed human T cells with

A

B

Figure 4. Characterization of CD8⁺CD28⁻ T cells generated from the primed human naive CD8⁺ T cells with allogeneic regulatory DCs. (A) Human allogeneic naive CD8⁺ T cells (5 × 10⁶) were cultured with allogeneic normal or regulatory DCs (5 × 10⁵) for 5 days, and CD8⁺ T cells isolated from the coculture were assayed for phenotype (left panel) and cytokine profile (right panel) by FACS. The results are representative of 5 experiments with similar results; data are represented by a dot plot. (B) CD8⁺CD28⁺ T cells or CD8⁺CD28⁻ T cells were isolated from the coculture of human naive CD8⁺ T cells (5 × 10⁶) with allogeneic normal mDCs or regulatory iDCs (5 × 10⁶) for 5 days. Ag-primed CD4⁺ T cells, CD8⁺CD28⁺ T cells, or CD8⁺CD28⁻ T cells (10⁵) were cultured with or without allogeneic normal mDCs (10⁴). In another experiment, Ag-primed CD4⁺ T cells (10⁵) were cultured with allogeneic normal mDCs (10⁴) in the presence or absence of different numbers of CD8⁺CD28⁺ T cells and CD8⁺CD28⁻ T cells in 96-well plates, and the proliferative response was measured on day 5. For Transwell experiments, CD8⁺CD28⁺ T cells or CD8⁺CD28⁻ T cells (10⁶) plus allogeneic normal mDCs (10⁵) were either added directly to the coculture of Ag-primed CD4⁺ T cells (10⁶) with allogeneic normal mDCs (10⁵) or were separated in 24-well plates. Following depletion of DCs, T cells (10⁵) were transferred to 96-well plates to measure the proliferative response on day 5. Data were expressed as mean values ± SD of 5 individual experiments. *P < .01 compared with Ag-primed CD4⁺ T cells plus allogeneic normal mDCs by Student paired t test. Error bars express SD of mean values.

murine regulatory DCs compared with the control group (P < .01). In addition, the survival period was significantly reduced when SCID mice received transplants of the primed human T cells with murine regulatory DCs in the presence of human IL-2 (P < .01).

We also examined the xenogeneic response of the transplanted human T cells obtained from the spleen in hu-PBL-SCID mice 10 days following xenogeneic transplantation against murine normal DCs (H-2ᵈ; Figure 5C). Analysis of the spleen in each group of hu-PBL-SCID mice showed that they were consistently engrafted with approximately 80% of human T cells at 10 days after xenogeneic transplantation. The xenogeneic response of the transplanted human T cells obtained from SCID mice receiving transplants of the primed human T cells with murine normal DCs was higher than that of human T cells obtained from hu-PBL-SCID mice. In contrast, the transplanted human T cells obtained from SCID mice transplanted with the primed human T cells with murine regulatory DCs had a poor xenogeneic response to murine normal DCs.

We further examined the therapeutic effect of a single injection with murine regulatory DCs following xenogeneic transplantation on the lethality caused by XGVHD in hu-PBL-SCID mice (Figure 5D). A single injection with murine regulatory DCs (4 × 10⁶/mouse) following xenogeneic transplantation had no effect on the engraftment of human T cells in spleen in hu-PBL-SCID mice. Interestingly, this injection prolonged the life span of hu-PBL-SCID mice compared with the control group (P < .01), whereas a single injection of the lower dose (< 4 × 10⁵/mouse) of murine regulatory DCs failed to exhibit a significant therapeutic effect (data not shown). We also observed that the sequential injections of human IL-2 abrogated their therapeutic effect. Similarly, a single injection with murine regulatory DCs (4 × 10⁶/mouse), but not murine normal DCs (4 × 10⁶/mouse), following allogeneic transplantation showed a therapeutic effect on the lethality caused by allogeneic acute GVHD (Figure 5E).

Discussion

Although DCs reportedly act as natural adjuvants to induce protective immunity against cancer and infectious diseases in humans, the strategy of the DC-mediated negative regulation of the T-cell response has not been established. To the best of our knowledge, this is the first paper to report that a group of human and murine DCs retain the potent immunoregulatory property in vitro and in vivo even under inflammatory conditions and show a protective effect on immunopathogenic disease.

We showed that the inflammatory stimulation failed to elicit a fully immunostimulatory maturational change in human regulatory iDCs, whereas the maturation-associated change in several cell surface molecules was observed. Therefore, the maturational process may be selectively impaired in human regulatory DCs.

Analysis of phenotype and function of normal DCs suggest that they could efficiently deliver potent signals to T-cell receptor for Ag (TCR) ligands (signal 1) and to costimulatory molecules (signal 2)[1,17] in alloreactive CD4⁺ T cells. In contrast, IL-10–treated iDCs[3,4] and 1α,25-dihydroxyvitamin D₃-treated iDCs[18] reportedly induced anergic CD4⁺ T cells in human in vitro. Furthermore, repetitive stimulation of human naive CD4⁺ T cells with allogeneic normal iDCs also generated anergic CD4⁺ T cells.[5] We showed that regulatory DCs exhibited moderately high levels of MHC molecules, whereas they exhibited little expression of costimulatory molecules as compared with their normal counterparts. Furthermore, regulatory DCs showed lower activation of allogeneic CD4⁺ T cells in the priming and more potent induction of their anergic state on restimulation with same donor-derived normal mDCs than IL-10–induced iDCs. These phenomena imply that the condition responsible for the induction of T-cell anergy by tolerant DCs is that the degree of T-cell activation in the priming is much lower than that on restimulation. Collectively, the characteristic expression profile of MHC and costimulatory molecules in regulatory DCs is associated with their potent ability to induce anergy, by which they may deliver potent signal 1 plus poor signal 2 to alloreactive CD4⁺ T cells.

We showed that priming with allogeneic normal mDCs enhanced the cytolytic activity of Ag-specific CD8⁺ T cells in an Ag-dependent manner. Therefore, allogeneic normal mDCs may activate these CD8⁺ T cells mediated through the delivery of potent signal 1 plus signal 2. On the other hand, the primed allogeneic Ag-specific CD8⁺ T cells with allogeneic regulatory DCs had reduced their activity in an Ag-dependent manner. Our results

Figure 5. Murine regulatory DCs induce T-cell anergy in human xenoreactive T cells. (A) Cells were stained with the stated mAbs or isotype-matched mAbs, and cell surface expression was analyzed by FACS. Data are represented by a histogram in which cells were stained with the stated mAbs (thick lines) or isotype-matched mAbs (thin lines). The values shown in the flow cytometry profiles are MFI. The results are representative of 5 individual experiments with similar results. (B) SCID mice received transplants of unprimed human T cells (●), human T cells primed with murine normal DCs (▲), human T cells primed with murine regulatory DCs (■), or human T cells primed with murine regulatory DCs plus human IL-2 at a T cell/DC ratio of 10:1 for 3 days (▼). Mice were monitored daily for survival. The results are representative of 2 individual experiments with similar results. $P < .01$ compared with hu-PBL-SCID mice by the Mann-Whitney U test). (C) Human T cells were obtained from the spleen in each group of hu-PBL-SCID mice on day 10 after xenogeneic transplantation. Isolated human T cells (10^5) were cultured with murine normal DCs (10^3 to 5×10^4), and the proliferative response was measured on day 5. Data were expressed as mean values ± SDs of 5 individual experiments. $*P < .01$ compared with human T cells plus murine normal DCs by Student paired t test. (D) The hu-PBL-SCID mice were injected with or without murine regulatory DCs (4×10^6/mouse) 2 days following xenogeneic transplantation. Alternatively, intravenous injections of human IL-2 (10^4U/mouse) were performed on days 3, 5, and 7 following xenogeneic transplantation in hu-PBL-SCID mice receiving murine regulatory DCs. Mice were monitored daily for survival. The results are representative of 2 individual experiments with similar results. $P < .01$ compared with hu-PBL-SCID mice by the Mann-Whitney U test. (E) SCID mice received transplants of murine allogeneic BM cells plus spleen mononuclear cells. Subsequently, the recipients were injected with or without murine normal or regulatory DCs (4×10^6/mouse) 2 days following allogeneic transplantation. Mice were monitored daily for survival. The results are representative of 2 individual experiments with similar results. $P < .01$ compared with untreated SCID mice that did not receive transplants by the Mann-Whitney U test.

suggest that regulatory DCs deliver potent signal 1 plus poor signal 2 to Ag-specific CD8[+] T cells, and that results in the induction of their anergic state.

Serial stimulations were needed for allogeneic normal iDCs to induce CD4[+]CD25[+] Tr cells from naive CD4[+] T cells.[5] On the other hand, we have recently reported that a single stimulation with IL-10–induced semimature DCs could induce CD4[+]CD25[+] Tr cells from the unprimed CD4[+] T cells.[4] We showed that a single stimulation with allogeneic regulatory DCs was sufficient for the efficient generation of CD4[+]CD25[+] Tr cells from naive CD4[+] T cells, indicating that regulatory DCs had a much more potent ability to induce CD4[+]CD25[+] Tr cells as compared with normal iDCs and IL-10–induced semimature DCs. On the other hand, the mechanism responsible for the generation of CD4[+] CD25[+] Tr cells from the primed naive CD4[+] T cells with allogeneic regulatory DCs remains unknown. Our results imply that allogeneic regulatory DCs may convert naive CD4[+] T cells into CD4[+]CD25[+] Tr cells. However, we cannot exclude the possibility that minimal numbers of CD4[+]CD25[+] T cells were included in cocultures. It is possible that allogeneic regulatory DCs may preferentially expand naturally existing CD4[+]CD25[+] T cells. Further study will be needed to test these possibilities.

The allogeneic regulatory DC-induced anergic state in CD4[+] T cells was partly restored by IL-2. CD4[+]CD25[+] Tr cells were reportedly unresponsive to IL-2.[19] Thus, this mechanism may involve the existence of CD4[+]CD25[+] Tr cells. On the other hand,

allogeneic regulatory DC-induced CD4[+]CD25[+] Tr cells caused the allogeneic Ag-specific and -nonspecific inhibitory effects. CD4[+]CD25[+] Tr cells are known to suppress the response of CD4[+] T cells in an Ag-nonspecific manner.[5,13,19] However, recent studies have shown the Ag-specific suppression of CD4[+]CD25[+] Tr cells in humans and animals.[20,21] Analysis of Ag specificity of the inhibitory effect of CD4[+]CD25[+] Tr cells showed that they exhibited both Ag-specific and Ag-nonspecific suppressive effects. These phenomena imply that the heterogeneity of allogeneic regulatory DC-induced CD4[+]CD25[+] Tr cells may reflect the requirement of Ag specificity for their effector function.

In contrast to IFN-γ–producing CD8[+]CD28[−] Tr cells[14-16] or IL-10–producing CD8[+] T cells,[6] CD8[+]CD28[−] Tr cells generated from the primed naive CD8[+] T cells with allogeneic regulatory DCs suppressed the activation of Ag-primed CD4[+] T cells, and they could produce IL-10. It has been suggested that CD8[+]CD28[−] Tr cells represent a distinct subset in a heterogeneous population.[15] These phenomena imply that the different types of allogeneic/ xenogeneic APCs may regulate the development of naive CD8[+] T cells into the distinct subsets of CD8[+]CD28[−] Tr cells.

The mechanism by which CD4[+]CD25[+] Tr and CD8[+]CD28[−] Tr cells exerted an inhibitory effect remains unclear although the mechanism of their action has been debated.[12,13]

Consistent with previous reports,[5,12,16] our results indicate that direct cell contact of these Tr cells with Ag-primed CD4[+] T cells, but not soluble factors secreted from these Tr cells, appears to be

essential for their suppressive capacity. Our results imply that the suppressive effect of these Tr cells may not be due to simple competition for APCs or IL-2. CD4$^+$CD25$^+$ Tr cells reportedly blocked the induction of IL-2 production by CD4$^+$CD25$^-$ T cells at the level of RNA transcription, and activation apparently enhanced the immunosuppressive function of these cells.[19] On the other hand, stimulation through the glucocorticoid-induced TNF receptor family-related gene abrogated the suppressive effects of CD4$^+$CD25$^+$ Tr cells.[22] Further study will be needed to clarify the mechanism responsible for their inhibitory effect.

We showed that hu-PBL-SCID mice succumbed to XGVHD, and the transplanted human T cells obtained from hu-PBL-SCID mice responded to murine normal DCs. Therefore, this xenogeneic response is likely to be mediated through a direct recognition of murine H-2^d MHC molecule of SCID mice by human T cells. Furthermore, in vitro priming with murine normal DCs not only enhanced xenogeneic response of human T cells to murine normal DCs but also promoted the lethality caused by XGVHD. These findings suggest that the priming with murine normal DCs up-regulates the ability of human T cells to cause a xenoreactive response.

In vitro priming with murine regulatory DCs impaired the ability of human T cells to respond to further stimulation with murine normal DCs as well as to induce XGVHD in hu-PBL-SCID mice. Analysis of SCID mice transplanted with the primed human T cells with murine regulatory DCs revealed that the transplanted human T cells retained an anergic state in vivo. In addition, a single injection with murine regulatory DCs following xenogeneic transplantation caused the therapeutic effect on the lethality caused by XGVHD in hu-PBL-SCID. On the other hand, these protected mice showed similar engraftment of human T cells to that of the control group, indicating that their protective effect may not be due to the failure of their engraftment mediated through the rejection/lysis of the human cells. Interestingly, host APCs reportedly play a crucial role in the initiation and progression of allogeneic acute GVHD, and their inactivation led to the prevention of allogeneic acute GVHD in the murine model.[23] Indeed, we showed that murine regulatory DCs also showed a protective effect on allogeneic acute GVHD. Therefore, our finding suggests that murine regulatory DCs could induce an anergic state in human xenoreactive T cells and murine alloreactive T cells, and that led to the protection of the recipients from the lethality caused by XGVHD as well as allogeneic acute GVHD. We also observed that in vitro or in vivo treatment with human IL-2 abrogated the protective effect of murine regulatory DCs on XGVHD in hu-PBL-SCID mice, and it is possibly mediated through the restoration of xenoreactivity of the transplanted human T cells.

In summary, regulatory DCs were potent regulators for T cell–mediated immunity in vivo and in vitro, and these cells retained their immunoregulatory property even once matured. Therefore, the strategy with self-Ag (peptides or protein)–pulsed autologous or allogeneic/xenogeneic regulatory DCs in humans may be useful for the prevention and the treatment of inflammation, autoimmune diseases, and allogeneic/xenogeneic organ transplantation. To test our hypothesis, preclinical studies with regulatory DCs in animal immunopathogenic models are being conducted in our laboratories.

Acknowledgments

References

1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767-811.

2. Sato K, Nagayama H, Tadokoro K, Juji T, Takahashi TA. Extracellular signal-regulated kinase, stress-activated protein kinase/c-Jun N-terminal kinase, and p38^{mapk} are involved in IL-10-mediated selective repression of TNF-α-induced activation and maturation of human peripheral blood monocyte-derived dendritic cells. J Immunol. 1999;162:3865-3872.

3. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997;159:4772-4780.

4. Sato K, Yamashita N, Matsuyama T. Human peripheral blood monocyte-derived interleukin-10-induced semi-mature dendritic cells induce anergic CD4$^+$ and CD8$^+$ T cells via presentation of the internalized soluble antigen and cross-presentation of the phagocytosed necrotic cellular fragments. Cell Immunol. 2002;215:186-194.

5. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, non-proliferating CD4$^+$ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213-1222.

6. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.

7. Roncarolo M-C, Levings MK, Traverari C. Differentiation of T regulatory cells by immature dendritic cells. J Exp Med. 2001;193:F5-F9.

8. Luz MB, Kukutsch N, Ogilvie ALJ, et al. An ad-

vanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92.

9. Sato K, Kawasaki H, Morimoto C, Yamashita N, Matsuyama T. An abortive ligand-induced activation of CC chemokine receptor (CCR)1-mediated downstream signaling event and a deficiency of CCR5 expression are associated with the hyporesponsiveness of human naive CD4$^+$ T cells to CLL3 and CCL5. J Immunol. 2002;168:6263-6272.

10. Sandhu JS, Gorczynski R, Shpitz B, Gallinger S, Nguyen H-P, Hozumi N. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes. Transplantation. 1995;60:179-184.

11. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455-458.

12. Shevach EM. Certified professionals: CD25$^+$CD4$^+$ suppressor T cells. J Exp Med. 2001;193:F41-F45.

13. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol. 2001;2:816-822.

14. Ciubotatiu R, Colovai AI, Pennesi G, et al. Specific suppression of human CD4$^+$ Th cell responses to pig MHC antigens by CD8$^+$CD28$^-$ regulatory T cells. J Immunol. 1998;161:5193-5202.

15. Colovai AI, Ciubotariu R, Liu Z, Cortesini R, Suciu-Foca N. CD8$^+$CD28$^-$ T suppressor cells represent a distinct subset in a heterogeneous population. Transpant Proc. 2001;33:104-107.

16. Chan CC, Ciubotariu R, Manavalan JS, et al.

Tolerization of dendritic cells by T$_S$ cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol. 2002;3:237-243.

17. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273:104-106.

18. Penna G, Adorini L. 1α,25-dihydroxyvitamin D$_3$ inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000;164:2405-2411.

19. Thornton AM, Shevach EM. CD25$^+$CD4$^+$ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.

20. Hori S, Haury M, Coutinho A, Demengeot J. Specificity requirements for selection and effector functions of CD25$^+$4$^+$ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. Proc Natl Acad Sci U S A. 2002;99:8213-8218.

21. Woo E, Yeh H, Chu CS, et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002;168:4272-4276.

22. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25$^+$CD4$^+$ regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol. 2002;3:135-142.

23. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.

Regulatory Dendritic Cells Protect Mice from Murine Acute Graft-versus-Host Disease and Leukemia Relapse

Katsuaki Sato,[1,5,*] Naohide Yamashita,[2]
Naomi Yamashita,[3] Masanori Baba,[4]
and Takami Matsuyama[1]
[1]Department of Immunology and Medical Zoology
School of Medicine
Kagoshima University
8-35-1 Sakuragaoka, Kagoshima City
Kagoshima 890-8520
[2]Department of Advanced Medical Science
The Institute of Medical Science
The University of Tokyo
4-6-1 Shirokanedai, Minato-ku
Tokyo 108-8639
[3]Department of Medicine
Teikyo University School of Medicine
2-11-1 Kaga, Itabashi-ku
Tokyo 173-8605
[4]Division of Human Retroviruses
Center for Chronic Viral Diseases
School of Medicine
Kagoshima University
8-35-1 Sakuragaoka, Kagoshima City
Kagoshima 890-8520
Japan

Summary

We have established a novel immunotherapeutic approach involving dendritic cells (DCs) with potent immunoregulatory property (designated as regulatory DCs [rDCs]) for acute graft-versus-host disease (GVHD) and leukemia relapse in allogeneic bone marrow (BM) transplantation (BMT) in mice bearing leukemia. rDCs displayed high levels of MHC molecules and extremely low levels of costimulatory molecules. A single injection of rDCs following allogeneic BMT controlled the ability of the transplanted T cells to induce acute GVHD and graft-versus-leukemia (GVL) effect in the recipients bearing leukemia, and that resulted in protection from the lethality caused by acute GVHD and tumor burden. Thus, the use of rDCs may be therapeutically useful for the treatment of acute GVHD and leukemia relapse in allogeneic BMT.

Introduction

Allogeneic bone marrow (BM) transplantation (BMT) is an effective treatment of leukemia as well as genetic disorders. However, its success is dependent on the prompt identification of a suitable donor and on the avoidance of opportunistic infections and severe graft-versus-host disease (GVHD) (Sato et al., 1999; Shlomchik et al., 1999). GVHD is mainly due to activation of alloreactive T cells in donor BM inoculum (Sato et al., 1999; Tsukada et al., 1999). Most therapeutic approaches designed to reduce acute GVHD have focused

*Correspondence: katsuaki@m3.kufm.kagoshima-u.ac.jp

on the development of immunosuppressive agents and the ex vivo removal of the unfractionated donor T cell population from the marrow graft (Lu et al., 2001). Although these strategies have reportedly reduced GVHD, there has been a reciprocal increase in the rate of graft rejection, more severe immunosuppression and lethal infections, as well as severe side effects (Lu et al., 2001). Furthermore, the risk of leukemia relapse could be increased in turn possibly due to the lack of an anti-leukemia effect of the allogeneic T cells infused, the so called graft-versus-leukemia (GVL) effect (Tsukada et al., 1999).

Normal mature dendritic cells (mDCs) are potent antigen (Ag)-presenting cells (APCs) to enhance T cell immunity whereas normal immature DCs (iDCs) are involved in the induction of peripheral T cell tolerance under steady state conditions (Banchereau et al., 2000; Hawiger et al., 2001; Roncarolo et al., 2001). However, the clinical application of normal iDCs may not be suitable for the treatment of immunopathogenic diseases, because they likely change into mature under inflammatory conditions (Roncarolo et al., 2001). Therefore, further development of DCs with a potent negative regulatory ability for T cells is thought to facilitate their use for treatment or prevention of immunopathologic diseases. We have recently established human and murine DCs with potent immunoregulatory property (designated as regulatory DCs [rDCs]) to impair the functions of alloreactive/xeno-reactive T cells (Sato et al., in press). In this study, we examined the therapeutic effect of murine rDCs on acute GVHD and leukemia relapse in allogeneic BMT in mice bearing leukemia.

Results

rDCs Impair T Cell Function

mDCs (H-2^d) showed high expression levels and percent positive cells for the DC marker (CD11c), costimulatory molecules (CD40, CD80, and CD86), and MHC molecules (I-K^d and I-A/I-E) (Table 1; Figure 1A), and a potent activation of allogeneic CD4$^+$ T cells (H-2^b or H-2^k) (Table 1; Figure 1B). In contrast, rDCs showed high expression levels of the DC marker and MHC molecules with extremely low levels of costimulatory molecules (Table 1; Figure 1A). Furthermore, rDCs (H-2^d) showed a lower activation of allogeneic CD4$^+$ T cells (H-2^b or H-2^k) than mDCs or 1α,25 dihydroxyvitamin D$_3$ (D$_3$)-conditioned DCs known as tolerant DCs (Penna and Adorini, 2000; Griffin et al., 2001) (Table 1; Figure 1B). We also observed similar phenotype and allogeneic T cell stimulatory capacity of rDCs in other strains (H-2^b or H-2^k) (Table 1).

We examined the effect of rDCs (H-2^d) on effector functions of in vivo-primed allogeneic CD4$^+$ T cells (H-2^b), which were obtained from the spleen of recipients (H-2^d) of BM cells plus spleen mononuclear cells (BMS, H-2^b) 5 days after transplantation. rDCs (H-2^d) inhibited mDC (H-2^d)-induced activation of in vivo-primed I-K^{b+}CD4$^+$ T cells in a dose-dependent manner, whereas the addition of mDCs (H-2^d) into the coculture of in vivo-

Table 1. Phenotype and Allogeneic T-Cell Capacity of rDCs

| Mouse Strain | Type of DCs | Mean % Positive Cells ± SD/MFI ± SD | | | | | | Allogeneic T Cell Stimulatory Capacity (cpm), T Cell (H-2b)/DC Ratio | | |
		CD40	CD11c	CD80	CD86	I-K	I-A and/or I-E	10:1	100:1	200:1
BALB/c mice (H-2d) (n = 10)	mDCs	68 ± 8/215 ± 45	58 ± 7/252 ± 33	84 ± 8/440 ± 53	77 ± 9/994 ± 74	86 ± 10/640 ± 75	77 ± 12/2405 ± 324	39547 ± 2414	15474 ± 1252	4321 ± 341
	rDCs	4 ± 2/14 ± 3	60 ± 5/243 ± 41	5 ± 3/23 ± 11	10 ± 3/36 ± 12	48 ± 10/359 ± 48	73 ± 11/1162 ± 187	541 ± 121	194 ± 64	154 ± 18
	D3-conditioned DCs	32 ± 5/130 ± 15	47 ± 5/178 ± 24	29 ± 6/111 ± 28	28 ± 7/257 ± 36	42 ± 5/284 ± 43	48 ± 6/687 ± 85	12654 ± 554	3354 ± 654	1145 ± 221
C57/BL6 mice (H-2b) (n = 10)	mDCs	65 ± 7/204 ± 34	61 ± 5/294 ± 41	80 ±10/387 ± 49	75 ± 8/979 ± 68	83 ± 12/628 ± 64	75 ± 14/2302 ± 287	35784 ± 1987	13421 ± 1754	3982 ± 405
DBA/1 mice (H-2q) (n = 10)	rDCs	3 ± 2/12 ± 5	54 ± 4/236 ± 45	4 ± 2/18 ± 9	8 ± 3/24 ± 7	47 ± 8/385 ± 51	74 ± 12/1089 ± 155	334 ± 84	144 ± 34	139 ± 64
	mDCs	64 ± 10/198 ± 33	63 ± 8/302 ± 48	76 ± 12/355 ± 42	72 ± 9/945 ± 54	81 ± 13/611 ± 58	74 ± 11/2159 ± 266	33541 ± 2154	11815 ± 1554	3451 ± 364
BALB/c mice (H-2d) (n = 10)	rDCs	3 ± 2/10 ± 4	51 ± 9/244 ± 32	5 ± 3/19 ± 8	7 ± 2/21 ± 6	46 ± 7/344 ± 53	71 ± 14/1124 ± 265	297 ± 14	133 ± 14	128 ± 34
	rDCs[b]	5 ± 3/18 ± 5	57 ± 7/231 ± 29	6 ± 2/30 ± 9	8 ± 4/42 ± 12	52 ± 12/378 ± 51	70 ± 8/1243 ± 194	425 ± 84	189 ± 72	121 ± 34

[a] The value of [3H]thymidine incorporation of T cells alone was less than 100 cpm.
[b] rDCs were obtained from the spleen in rDC (H-2q)-treated recipients (H-2q) of allogeneic BMS (H-2q) 5 days after transplantation as described in Experimental Procedures.

primed I-Kb+CD4+ T cells and mDCs (H-2q) slightly enhanced this response (Figure 1C). On the other hand, the coculture with mDCs obtained from different strains (H-2d and H-2q) additively enhanced the response of these I-Kb+CD4+ T cells whereas the addition of rDCs (H-2q) had little or no effect on their response to mDCs (H-2q), indicating that this rDC-mediated regulation is Ag specific. Similar results were observed in other strain combinations (Figure 1D; see supplemental data at http://www.immunity.com/cgi/content/full/18/3/367/DC1).

We also examined the effect of rDCs (H-2q) on cytotoxic T lymphocyte (CTL) activity of in vivo-primed allogeneic CD8+ T cells (H-2b) obtained from the recipients (H-2q) of BMS (H-2b) as described above. In vivo-primed I-Kb+CD8+ T cells showed CTL activity against P815 cells (H-2d), but not EL4 cells (H-2b) and concanavalin A (Con A) blasts (H-2q) (Figure 1E), indicating that their cytotoxicity was H-2d specific. Furthermore, the cytotoxic activity of in vivo-primed I-Kb+CD8+ T cells against P815 cells was suppressed when cocultured with rDCs (H-2q), whereas mDCs (H-2q) caused their further activation (Figure 1E; see supplemental data at http://www.immunity.com/cgi/content/full/18/3/367/DC1). In addition, treatment with mDCs or rDCs obtained from syngeneic (H-2b) and third party (H-2q) strains did not affect their activity (Figure 1E). These results indicate that the regulation of CTL activity by rDCs is Ag specific. Similar results were observed in other strain combinations (Figure 1F).

We further examined the ability of rDCs to induce a tolerance in allogeneic CD4+ T cells (Figure 1G). Allogeneic CD4+ T cells (H-2b) stimulated with mDCs (H-2q) in a first coculture responded vigorously to restimulation with mDCs (H-2q). In contrast, allogeneic CD4+ T cells (H-2b) primed with rDCs (H-2q) were hyporesponsive to further stimulation with mDCs (H-2q). Furthermore, the addition of interleukin (IL)-2 to a second culture partly enhanced this response when rDCs were used as APCs in the priming. On the other hand, CD4+ T cells (H-2b) primed with mDCs (H-2q) exhibited a similar response to mDCs (H-2q or H-2k) in a second culture to that of unprimed allogeneic CD4+ T cells (H-2b) with mDCs (H-2q or H-2k) in the first coculture whereas CD4+ T cells (H-2b) primed with rDCs (H-2q) exhibited slightly lower response to mDCs (H-2q or H-2k). We also observed similar results in other strain combinations (Figure 1H). In addition, the degree of rDC-induced T cell hyporesponsiveness was higher than that of D3-conditioned DCs (Figure 1G; see supplemental data at http://www.immunity.com/cgi/content/full/18/3/367/DC1). These results indicate that rDCs are potent APCs to induce tolerant T cells as well as to suppress the activation of effector T cells.

rDCs Protected the Recipients of Allogeneic BMS from the Lethality Caused by Acute GVHD
To clarify the therapeutic effect of rDCs on acute GVHD in allogeneic BMT, we examined the effect of a single injection of rDCs (H-2q) on the lethality caused by acute GVHD in the recipients (H-2q) of BMS (H-2b). All recipients of allogeneic BMS died on day 8 following transplantation (Figure 2A). In these mice, clinical symptoms of acute GVHD, such as hair ruffling, lower mobility, and